Danaher settles shareholder lawsuit for 172.5 million
The diagnostics company reached a preliminary settlement to resolve claims it misled investors about bioprocessing demand. Danaher denies any wrongdoing in the case.
Xurve View
Insights:
Xurve View
DANAHER CORP has reached a $172.5 million preliminary settlement with shareholders who alleged the diagnostics and life-sciences firm misled investors regarding its post-pandemic growth prospects. The all-cash agreement, filed in a federal court in the United States in Washington, D.C., awaits final judicial approval.
